Nutrition

(asked on 23rd March 2022) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what the Advisory Committee on Borderline Substances' pricing policy for medical nutrition products is; and whether this pricing policy is applied equally to all companies producing those products.


Answered by
Edward Argar Portrait
Edward Argar
Minister of State (Ministry of Justice)
This question was answered on 28th March 2022

The Advisory Committee on Borderline Substances pricing policy governs the pricing of all borderline substances listed in Part XV of the Drug Tariff. The terms of the policy are dependent on the type of product application. Type 1 applications relate to new formulations where there is no comparable product on the market and the applicant proposes a price. Type 2 applications are for formulations similar to formulations on the market and the applicant compares the price with those of similar formulations. Type 3 applications are for products on the market that the manufacturer wants to change or increase in price. Products can increase in price once every 12 months in line the current Retail Price Index (excluding mortgages) or an average of the preceding 12 months, whichever is higher. Manufacturers can apply for increases above this benchmark provided it can be evidenced that it will save money for the National Health Service. These terms apply equally to all manufacturers.

Reticulating Splines